TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Gordie Howe Bridge to Open July 27 After U.S.-Canada Reach Toll Revenue Agreement 
Iraq PM Visits Washington as U.S. Oil, Gas Deals Take Center Stage 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
BOJ May Raise Japan Growth Forecast While Keeping Focus on Inflation Risks 
Goldman Sees Foreign Investors Driving India Stock Market Recovery 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Dollar Holds Steady Ahead of U.S. CPI as Oil Surge, Middle East Tensions Keep Markets on Edge 
Dollar Eases as Middle East Conflict, Fed Outlook and Japan Pension Policy Drive FX Markets 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Japanese Yen Holds Steady as Intervention Hopes Grow Ahead of U.S. CPI Data 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Novo Nordisk, a Danish pharmaceutical firm based in Bagsværd, Denmark, announced on Thursday, Aug. 10, that it will buy privately held the Canadian obesity drug manufacturer Inversago Pharma.
The company said the deal may be worth up to $1.08 billion. Novo Nordisk said there is no exact price yet as of this time because the determination will depend on whether Inversago Pharma is able to achieve certain development and target sales.
CNBC reported that the firms are looking to close the deal before 2023 ends. Novo Nordisk’s decision to acquire the Canadian company is a strategic move to further widen its weight loss portfolio.
The transaction also comes after its Wegovy prescription medication for adults with obesity and Ozempic weight loss injectibles’ popularity took off to great heights. The company is taking advantage of this achievement and aims to keep this momentum going by adding Inversago Pharma and its products into its own weight loss and obesity treatment offering lineup.
“The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders,” Novo Nordisk’s executive vice president for development, Martin Holst Lange, commented in a press release. “This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity.”
Finally, François Ravenelle, Inversago Pharma’s chief executive officer, also said they “are delighted to join forces with a global leader in the obesity and metabolic disorder space. It added that they “believe this combination will help unlock the full medical potential of their CB1 blockers and may one day expand treatment options for people living with metabolic syndrome, obesity, and related complications.”
Photo by: Novo Nordisk Media Library
